Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice

Qing-Shuo Zhang, Weiliang Tang, Matthew Deater, Ngoc Phan, Andrea N. Marcogliese, Hui Li, Muhsen Al-Dhalimy, Angela Major, Susan Olson, Raymond J. Monnat, Markus Grompe

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Fanconi anemia (FA) is an inherited bone marrow failure disorder associated with a high incidence of leukemia and solid tumors. Bone marrow transplantation is currently the only curative therapy for the hematopoietic complications of this disorder. However, long-term morbidity and mortality remain very high, and new therapeutics are badly needed. Here we show that the widely used diabetes drug metformin improves hematopoiesis and delays tumor formation in Fancd2-/- mice. Metformin is the first compound reported to improve both of these FA phenotypes. Importantly, the beneficial effects are specific to FA mice and are not seen in the wild-type controls. In this preclinical model of FA, metformin outperformed the current standard of care, oxymetholone, by improving peripheral blood counts in Fancd2-/- mice significantly faster. Metformin increased the size of the hematopoietic stem cell compartment and enhanced quiescence in hematopoietic stem and progenitor cells. In tumor-prone Fancd2-/- Trp53+/- mice, metformin delayed the onset of tumors and significantly extended the tumor-free survival time. In addition, we found that metformin and the structurally related compound aminoguanidine reduced DNA damage and ameliorated spontaneous chromosome breakage and radials in human FA patient-derived cells. Our results also indicate that aldehyde detoxification might be one of the mechanisms by which metformin reduces DNA damage in FA cells.

Original languageEnglish (US)
Pages (from-to)2774-2784
Number of pages11
JournalBlood
Volume128
Issue number24
DOIs
StatePublished - Dec 15 2016

Fingerprint

Fanconi Anemia
Metformin
Hematopoiesis
Tumors
Hematopoietic Stem Cells
Neoplasms
DNA Damage
Oxymetholone
Bone
Chromosome Breakage
Detoxification
DNA
Standard of Care
Chromosomes
Medical problems
Stem cells
Bone Marrow Transplantation
Aldehydes
Leukemia
Blood

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice. / Zhang, Qing-Shuo; Tang, Weiliang; Deater, Matthew; Phan, Ngoc; Marcogliese, Andrea N.; Li, Hui; Al-Dhalimy, Muhsen; Major, Angela; Olson, Susan; Monnat, Raymond J.; Grompe, Markus.

In: Blood, Vol. 128, No. 24, 15.12.2016, p. 2774-2784.

Research output: Contribution to journalArticle

Zhang, Q-S, Tang, W, Deater, M, Phan, N, Marcogliese, AN, Li, H, Al-Dhalimy, M, Major, A, Olson, S, Monnat, RJ & Grompe, M 2016, 'Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice', Blood, vol. 128, no. 24, pp. 2774-2784. https://doi.org/10.1182/blood-2015-11-683490
Zhang Q-S, Tang W, Deater M, Phan N, Marcogliese AN, Li H et al. Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice. Blood. 2016 Dec 15;128(24):2774-2784. https://doi.org/10.1182/blood-2015-11-683490
Zhang, Qing-Shuo ; Tang, Weiliang ; Deater, Matthew ; Phan, Ngoc ; Marcogliese, Andrea N. ; Li, Hui ; Al-Dhalimy, Muhsen ; Major, Angela ; Olson, Susan ; Monnat, Raymond J. ; Grompe, Markus. / Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice. In: Blood. 2016 ; Vol. 128, No. 24. pp. 2774-2784.
@article{f118da34303b4283ad71638fd7cf6799,
title = "Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice",
abstract = "Fanconi anemia (FA) is an inherited bone marrow failure disorder associated with a high incidence of leukemia and solid tumors. Bone marrow transplantation is currently the only curative therapy for the hematopoietic complications of this disorder. However, long-term morbidity and mortality remain very high, and new therapeutics are badly needed. Here we show that the widely used diabetes drug metformin improves hematopoiesis and delays tumor formation in Fancd2-/- mice. Metformin is the first compound reported to improve both of these FA phenotypes. Importantly, the beneficial effects are specific to FA mice and are not seen in the wild-type controls. In this preclinical model of FA, metformin outperformed the current standard of care, oxymetholone, by improving peripheral blood counts in Fancd2-/- mice significantly faster. Metformin increased the size of the hematopoietic stem cell compartment and enhanced quiescence in hematopoietic stem and progenitor cells. In tumor-prone Fancd2-/- Trp53+/- mice, metformin delayed the onset of tumors and significantly extended the tumor-free survival time. In addition, we found that metformin and the structurally related compound aminoguanidine reduced DNA damage and ameliorated spontaneous chromosome breakage and radials in human FA patient-derived cells. Our results also indicate that aldehyde detoxification might be one of the mechanisms by which metformin reduces DNA damage in FA cells.",
author = "Qing-Shuo Zhang and Weiliang Tang and Matthew Deater and Ngoc Phan and Marcogliese, {Andrea N.} and Hui Li and Muhsen Al-Dhalimy and Angela Major and Susan Olson and Monnat, {Raymond J.} and Markus Grompe",
year = "2016",
month = "12",
day = "15",
doi = "10.1182/blood-2015-11-683490",
language = "English (US)",
volume = "128",
pages = "2774--2784",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "24",

}

TY - JOUR

T1 - Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice

AU - Zhang, Qing-Shuo

AU - Tang, Weiliang

AU - Deater, Matthew

AU - Phan, Ngoc

AU - Marcogliese, Andrea N.

AU - Li, Hui

AU - Al-Dhalimy, Muhsen

AU - Major, Angela

AU - Olson, Susan

AU - Monnat, Raymond J.

AU - Grompe, Markus

PY - 2016/12/15

Y1 - 2016/12/15

N2 - Fanconi anemia (FA) is an inherited bone marrow failure disorder associated with a high incidence of leukemia and solid tumors. Bone marrow transplantation is currently the only curative therapy for the hematopoietic complications of this disorder. However, long-term morbidity and mortality remain very high, and new therapeutics are badly needed. Here we show that the widely used diabetes drug metformin improves hematopoiesis and delays tumor formation in Fancd2-/- mice. Metformin is the first compound reported to improve both of these FA phenotypes. Importantly, the beneficial effects are specific to FA mice and are not seen in the wild-type controls. In this preclinical model of FA, metformin outperformed the current standard of care, oxymetholone, by improving peripheral blood counts in Fancd2-/- mice significantly faster. Metformin increased the size of the hematopoietic stem cell compartment and enhanced quiescence in hematopoietic stem and progenitor cells. In tumor-prone Fancd2-/- Trp53+/- mice, metformin delayed the onset of tumors and significantly extended the tumor-free survival time. In addition, we found that metformin and the structurally related compound aminoguanidine reduced DNA damage and ameliorated spontaneous chromosome breakage and radials in human FA patient-derived cells. Our results also indicate that aldehyde detoxification might be one of the mechanisms by which metformin reduces DNA damage in FA cells.

AB - Fanconi anemia (FA) is an inherited bone marrow failure disorder associated with a high incidence of leukemia and solid tumors. Bone marrow transplantation is currently the only curative therapy for the hematopoietic complications of this disorder. However, long-term morbidity and mortality remain very high, and new therapeutics are badly needed. Here we show that the widely used diabetes drug metformin improves hematopoiesis and delays tumor formation in Fancd2-/- mice. Metformin is the first compound reported to improve both of these FA phenotypes. Importantly, the beneficial effects are specific to FA mice and are not seen in the wild-type controls. In this preclinical model of FA, metformin outperformed the current standard of care, oxymetholone, by improving peripheral blood counts in Fancd2-/- mice significantly faster. Metformin increased the size of the hematopoietic stem cell compartment and enhanced quiescence in hematopoietic stem and progenitor cells. In tumor-prone Fancd2-/- Trp53+/- mice, metformin delayed the onset of tumors and significantly extended the tumor-free survival time. In addition, we found that metformin and the structurally related compound aminoguanidine reduced DNA damage and ameliorated spontaneous chromosome breakage and radials in human FA patient-derived cells. Our results also indicate that aldehyde detoxification might be one of the mechanisms by which metformin reduces DNA damage in FA cells.

UR - http://www.scopus.com/inward/record.url?scp=85014904838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014904838&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-11-683490

DO - 10.1182/blood-2015-11-683490

M3 - Article

C2 - 27756748

AN - SCOPUS:85014904838

VL - 128

SP - 2774

EP - 2784

JO - Blood

JF - Blood

SN - 0006-4971

IS - 24

ER -